Finance

Lists
AORT:NYSE
Artivion Inc
21,36 $
-1,97%
(-0,43) 1D
21,36 $
0,00% (0,00)
After hours
Closed: 13 қаз., 16:00:07 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AORT...
Open
21,83 $
High
22,40 $
Low
21,30 $
Mkt. cap
1,04 млрд
Avg. vol.
598,06 м.
Volume
663,26 м.
52-wk high
48,25 $
52-wk low
19,16 $
EPS
-0,07 $
Beta
1,23
Shares outstanding
48,76 млн
No. of employees
2 мың
Open
21,83 $
High
22,40 $
Low
21,30 $
Mkt. cap
1,04 млрд
Avg. vol.
598,06 м.
Volume
663,26 м.
52-wk high
48,25 $
52-wk low
19,16 $
EPS
-0,07 $
Beta
1,23
Shares outstanding
48,76 млн
No. of employees
2 мың
News stories
From web sources and news partners
Profile
Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive. Wikipedia
About Artivion Inc
CEOJames Patrick Mackin
Employees1,8 мың
Founded1984
HeadquartersKennesaw, Джорджия, Америка Құрама Штаттары
SectorMedical device
Analyst ratings
Based on 6 analysts giving stock ratings to AORT in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AORT in the last 3 months.
Highest
Current 21,36 $
45,00 $ (+110,67%)
Average
41,87 $ (+96,02%)
Lowest
38,00 $ (+77,90%)
Analyst
Recommendation
Action
Price target
Projected
Date
William Plovanic
Canaccord Genuity
Buy
Maintained
40,00 $
+87,3%
08/18/2026
Jeffrey Cohen
Ladenburg Thalmann & Co.
Buy
Maintained
39,20 $
+83,5%
08/07/2026
Frank Takkinen
Lake Street
Buy
Reiterated
45,00 $
+110,7%
08/07/2026
Suraj Kalia
Oppenheimer
Buy
Reiterated
38,00 $
+77,9%
08/07/2026
Rick Wise
Stifel Nicolaus
Buy
Reiterated
45,00 $
+110,7%
08/07/2026
Michael Matson
Needham
Buy
Reiterated
44,00 $
+106%
08/07/2026
Daniel Stauder
Citizens JMP
Buy
Maintained
48,00 $
+124,7%
05/08/2026
Eric Martinuzzi
Lake Street
Buy
Reiterated
55,00 $
+157,5%
04/08/2026
Last report
2026 ж. 06 там.
Fiscal period
Q2 2026
0,13 $ / 0,10 $
+34,48%beat
Revenue / Est. (USD)
125,76 млн / 120,01 млн
+4,79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
113,39 млн
115,99 млн
116,34 млн
125,76 млн
Cost of goods sold
38,99 млн
42,85 млн
40,89 млн
45,24 млн
Cost of revenue
38,99 млн
42,85 млн
40,89 млн
45,24 млн
Research and development expenses
8,08 млн
9,12 млн
8,84 млн
9,06 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
54,68 млн
54,64 млн
60,58 млн
60,13 млн
Operating expense
62,76 млн
63,76 млн
69,42 млн
69,18 млн
Total operating expenses
101,75 млн
106,61 млн
110,31 млн
114,42 млн
Operating income
11,64 млн
9,38 млн
6,03 млн
11,34 млн
Other non operating income
499,00 м.
1,18 млн
514,00 м.
-49,00 мың
EBT including unusual items
7,06 млн
6,54 млн
339,00 м.
-11,70 млн
EBT excluding unusual items
6,16 млн
5,15 млн
579,00 м.
3,70 млн
Income tax expense
554,00 м.
4,11 млн
-1,08 млн
1,81 млн
Effective tax rate
7,85%
62,89%
-317,99%
-15,48%
Other operating expenses
-
-
-
-
Net income
6,50 млн
2,43 млн
1,42 млн
-13,51 млн
Net profit margin
5,73%
2,09%
1,22%
-10,74%
Earnings per share
0,16
0,17
0,08
0,13
Interest and investment income
240,00 м.
311,00 м.
205,00 м.
367,00 м.
Interest expense
-6,12 млн
-5,62 млн
-5,37 млн
-7,25 млн
Net interest expenses
-5,88 млн
-5,31 млн
-5,16 млн
-6,89 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
17,35 млн
15,14 млн
12,37 млн
18,08 млн
Gain or loss from assets sale
-3,50 млн
-3,50 млн
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары